Chronic Lymphocytic Leukemia

BGB-16673 showed a favorable safety profile and promising antitumor activity in relapsed/refractory CLL/SLL, with responses seen across baseline mutations.

The FDA has approved a tablet formulation of zanubrutinib for use in all 5 approved indications of the capsule formulation.

Time-limited therapy with acalabrutinib plus venetoclax with or without obinutuzumab is approved in the European Union for untreated patients with CLL.

Zanubrutinib in combination with venetoclax was highly active in patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Zanubrutinib retained long-term efficacy as a frontline treatment in CLL/SLL harboring 17p deletions.

Zanubrutinib showed high response rates and durable responses among Japanese patients with CLL/SLL and Waldenström macroglobulinemia.

The top 5 OncLive videos of the week cover insights in ovarian cancer, prostate cancer, chronic lymphocytic leukemia, and breast cancer.

Seema A. Bhat, MD, discusses the lack of highly effective treatment options for patients with double-refractory CLL.

BTK mutations occurred at low rates in patients with CLL who had disease progression after receiving zanubrutinib or ibrutinib in the phase 3 ALPINE study.

Nicole Lamanna, MD, discusses pirtobrutinib decision-making in the relapsed/refractory CLL setting and ongoing earlier-line research with the agent.

Mazyar Shadman, MD, MPH, discusses the rationale and methodological framework of a network meta analysis of BTK inhibitors in relapsed/refractory CLL.

The EMA’s CHMP has recommended the approval for acalabrutinib/venetoclax with or without obinutuzumab in untreated CLL.

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.

Matthew Cortese, MD, MPH, discusses the rationale for an analysis of the immunologic activity of venetoclax in patients with chronic lymphocytic leukemia.

China’s NMPA has approved orelabrutinib for the first-line treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.

A network meta analysis compared the efficacy of BTK inhibitors in patients with high-risk R/R chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses the rationale and methodological framework of a network meta-analysis aimed at evaluating the comparative efficacy of BTK inhibitors in R/R CLL.

Nogapendekin alfa inbakicept sBLA in NMIBC has been filed to FDA for review, a bexmarilimab combination elicits responses in MDS, and more from OncLive.

Francisco J. Hernandez-Ilizaliturri, MD, discusses the rationale behind assessing immunologic changes seen with venetoclax treatment in patients with CLL.

Alvaro Alencar, MD, discusses research needed to clarify the optimal dosing, role, and sequencing of NX-5948 in CLL and other B-cell malignancies.

Zanubrutinib plus venetoclax and obinutuzumab was well tolerated—aside from COVID-19–related toxicities—in patients with relapsed/refractory CLL.

Stephen Opat, MBBS, explains the unique mechanism of action of sonrotoclax and how it differs from venetoclax for the treatment of patients with relapsed/refractory CLL or SLL.

Paolo Ghia, MD, PhD, discusses ongoing and future directions for the investigation of fixed-duration ibrutinib/venetoclax in CLL.

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.

Matthew Cortese, MD, MPH, discusses the methods used to produce a comprehensive map of immune changes that occur with venetoclax treatment in CLL.

Paolo Ghia, MD, PhD, discusses long-term data for fixed-duration ibrutinib plus venetoclax in chronic lymphocytic leukemia.

Acalabrutinib was effective in a population of patients from China with relapsed/refractory CLL.

Catherine C. Coombs, MD, discusses the need to establish a standardized definition of high-risk CLL.

Alvaro Alencar, MD, discusses current unmet needs following the development of covalent BTK inhibitor resistance in CLL.

Acalabrutinib with venetoclax and obinutuzumab was effective and well tolerated in treatment-naive CLL harboring a TP53 aberration.